2018
Development and Validation of LC–MS-MS Assay for the Determination of the Emerging Alkylating Agent Laromustine and Its Active Metabolite in Human Plasma
Nassar AF, Wisnewski AV, Wu T, Lam TT, King I. Development and Validation of LC–MS-MS Assay for the Determination of the Emerging Alkylating Agent Laromustine and Its Active Metabolite in Human Plasma. Journal Of Chromatographic Science 2018, 57: 195-203. PMID: 30395213, DOI: 10.1093/chromsci/bmy100.Peer-Reviewed Original Research
2016
Population pharmacokinetic (PK) analysis of laromustine, an emerging alkylating agent, in cancer patients
Nassar AF, Wisnewski AV, King I. Population pharmacokinetic (PK) analysis of laromustine, an emerging alkylating agent, in cancer patients. Xenobiotica 2016, 47: 394-407. PMID: 27440490, DOI: 10.1080/00498254.2016.1201703.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, AlkylatingFemaleHumansHydrazinesMaleMiddle AgedModels, BiologicalProdrugsSulfonamidesConceptsPopulation pharmacokinetic analysisInter-patient variabilityPharmacokinetic analysisSignificant single-agent activitySingle-agent activityPopulation PK analysisVolume of distributionHigh inter-patient variabilityInter-occasion variabilityAlkylating agentCancer patientsTotal clearanceTotal body waterClinical trialsHematologic malignanciesPK analysisDosing cyclesOrgan functionSolid tumorsAntineoplastic alkylating agentCentral compartmentNONMEM analysisRapid clearancePatientsClearanceBiotransformation and Rearrangement of Laromustine
Nassar AE, Wisnewski AV, King I. Biotransformation and Rearrangement of Laromustine. Drug Metabolism And Disposition 2016, 44: 1349-1363. PMID: 27278961, DOI: 10.1124/dmd.116.069823.Peer-Reviewed Original ResearchConceptsNuclear magnetic resonance spectroscopyCollision-induced dissociationFourier transform ion cyclotron resonance mass spectrometerIon cyclotron resonance mass spectrometerAccurate mass measurementsMass spectrometry studiesHydrogen-deuterium exchangeMagnetic resonance spectroscopyMass spectral rearrangementsExact massSpectrometry studiesEnzyme catalysisReactive intermediatesMass spectrometerDecomposition productsResonance spectroscopyConjugation reactionsElemental compositionPossibility of rearrangementMass measurementsSpectral rearrangementsDissociationRadioactive componentsLoss of nitrogenMetabolite products
2015
Metabolic disposition of the anti-cancer agent [14C]laromustine in male rats
Nassar AF, Wisnewski A, King I. Metabolic disposition of the anti-cancer agent [14C]laromustine in male rats. Xenobiotica 2015, 45: 711-721. PMID: 25798740, PMCID: PMC4681490, DOI: 10.3109/00498254.2015.1016475.Peer-Reviewed Original ResearchConceptsQuantitative whole-body autoradiographyBolus doseDrug-derived radioactivityPeak plasma concentrationWhole-body autoradiographyGroup 1 animalsUrinary bladder contentsLong-Evans ratsExcretion of drugsSmall intestine contentsRecovery of radioactivityNovel sulfonylhydrazineAnti-cancer agentsSpinal cordMale ratsPlasma concentrationsIntravenous administrationRenal cortexBladder contentsTotal bodyMetabolic dispositionOrgan exposureSmall intestineRatsMedical guidelines